局部进展期胃癌的新辅助化疗：现状分析；来自意大利单中心的观点。
Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Where we Stand; An Italian Single Center Perspective.
机构信息
General and Emergency Surgery, University of Perugia, Perugia, Italy
General and Emergency Surgery, University of Perugia, Perugia, Italy.
出版信息
In Vivo. 2021 Nov-Dec;35(6):3459-3466. doi: 10.21873/invivo.12646.
BACKGROUND/AIM: Neoadjuvant or perioperative chemotherapy is the standard treatment for locally advanced gastric cancer. However, in Eastern countries this is still debated. The aim of our study was to evaluate the survival impact of neoadjuvant chemotherapy.
PATIENTS AND METHODS
A total of 60 patients who underwent preoperative chemotherapy were compared to patients with locally advanced gastric cancer that underwent upfront surgery.
RESULTS
Median survival of the entire group curatively treated was 41 months with a median progression-free survival of 38 months. By excluding patients with stage IV disease from the neoadjuvant group, a statistically significant difference was reached both in terms of overall survival and disease-free survival. By subdividing patients according to pTNM stages, neoadjuvant patients showed better survival in stage I and II.
CONCLUSION
Neoadjuvant chemotherapy could be an effective treatment for locally advanced disease. However, randomized studies are still needed to fully understand its role and identify patients that will benefit from it.
背景/目的：新辅助或围手术期化疗是局部晚期胃癌的标准治疗方法。然而，在东方国家，这仍然存在争议。本研究的目的是评估新辅助化疗对生存的影响。
患者和方法
共比较了 60 例接受术前化疗的患者和接受局部晚期胃癌根治性手术的患者。
结果
整个可治愈治疗组的中位生存期为 41 个月，无进展生存期的中位数为 38 个月。通过排除新辅助组中 IV 期疾病的患者，在总生存期和无病生存期方面均达到了统计学显著差异。根据 pTNM 分期将患者细分，新辅助组患者在 I 期和 II 期的生存情况更好。
结论
新辅助化疗可能是局部晚期疾病的有效治疗方法。然而，仍需要进行随机研究，以充分了解其作用并确定从中受益的患者。
Zotero 插件